Step-wise loss of antidepressant effectiveness with repeated antidepressant trials in bipolar II depression-Reference-Cited by-同舟云学术

Step-wise loss of antidepressant effectiveness with repeated antidepressant trials in bipolar II depression

Published:2016-11 Issue:7 Volume:18 Page:563-570
ISSN:1398-5647
Container-title:Bipolar Disorders
language:en
Short-container-title:Bipolar Disord

Author:

Amsterdam Jay D¹,Lorenzo-Luaces Lorenzo¹²³,DeRubeis Robert J¹²

Affiliation:

1. Depression Research Unit; Department of Psychiatry; Perelman School of Medicine; University of Pennsylvania School of Medicine; Philadelphia PA USA

2. Department of Psychology; University of Pennsylvania; Philadelphia PA USA

3. Methods to Improve Diagnostic Assessment and Services (MIDAS) Project; Brown University; Providence RI USA

Funder

National Institute of Mental Health

University of Pennsylvania

Jack Warsaw Fund for Research in Biological Psychiatry

Publisher

Wiley

Subject

Biological Psychiatry,Psychiatry and Mental health

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bdi.12442/fullpdf

Reference41 articles.

1. Fluoxetine efficacy in treatment resistant depression;Amsterdam;Prog Neuro-Psychopharmacol Biol Psychiat.,1994

2. Does tachyphylaxis occur after repeated antidepressant exposure in patients with Bipolar II major depressive episode?;Amsterdam;J Affect Disord.,2009

3. Dual reuptake inhibitors incur lower rates of tachyphylaxis than selective serotonin reuptake inhibitors;Posternak;J Clin Psychiatry.,2005

4. Tachyphylaxis in unipolar major depressive disorder;Solomon;J Clin Psychiatry.,2005

5. Loss of response to antidepressants and subsequent refractoriness: diagnostic issues in a retrospective case series;Sharma;J Affect Disord.,2001

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Disease progression to bipolar disorder among adolescents and young adults with antidepressant-resistant and antidepressant-responsive depression: Does antidepressant class matter?;European Neuropsychopharmacology;2023-09

2. What are the treatment remission, response and extent of improvement rates after up to four trials of antidepressant therapies in real-world depressed patients? A reanalysis of the STAR*D study’s patient-level data with fidelity to the original research protocol;BMJ Open;2023-07

3. Pharmacotherapy exposure as a marker of disease complexity in bipolar disorder: Associations with clinical & genetic risk factors;Psychiatry Research;2023-05

4. More Treatment, but Not Less Anxiety and Mood Disorders: Why? Seven Hypotheses and Their Evaluation;Psychotherapy and Psychosomatics;2023

5. Effectiveness and safety of monoamine oxidase inhibitor treatment for bipolar depression versus unipolar depression: An exploratory case cohort study;Acta Psychiatrica Scandinavica;2022-11-12